CXCL9 as a key feature for deep learning-based immune subtyping and prediction of immune checkpoint blockade response in triple-negative breast cancer
Our study developed a novel immune classification system for TNBC, identifying CXCL9 as a key biomarker positively correlated with ICB response and regulated by IDO1. These findings provide a basis for precision immunotherapy in TNBC and support the exploration of IDO1 inhibitors in combination with ICB.
Authors
- Linxin Teng (ORCID: https://orcid.org/0000-0002-2948-3179)
- Biao Xu (ORCID: https://orcid.org/0000-0001-7259-298X)
- Suchen Qu
- Yizhen Deng
- Rongming Jiang
- Chengyan Wu
- Yu Li
- Qingwu Shi
- Juan Li
- Wen Jin
- Yanmei Zhu
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Nanjing University of Chinese Medicine (CN)
- Guangdong Provincial Hospital of Traditional Chinese Medicine (CN)
- Anshan Hospital (CN)
Publication Details
- Journal
- International Immunopharmacology
- Published
- 2026-02-26
- DOI
- https://doi.org/10.1016/j.intimp.2026.116439
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00